Adherex Gets Regulatory Clearance for Phase II Trial of ADH-1 in Canada

Health Canada has given regulatory clearance for the Adherex Technologies' Phase II clinical trial application for ADH-1, the company's lead antitumor biotechnology compound, also known as Exherin.

The Phase II trial, which is expected to involve up to three cancer centers in Canada, will investigate repeated doses of ADH-1 in an every three-week dosing schedule in patients whose tumors express the molecular target N-cadherin.

Specifically, the company will study eight different tumor types, including some more common ones such as breast and lung, as well as some rarer cancers such as adrenocortical and esophageal cancer. This trial, the first in the company's Phase II program, is expected to enroll up to 60 patients.